GlassScriptPhysician profile
Cherez Pouncey
NPI 1407324700
$2,610.14
in general payments reported to CMS, 2019-2025
19 companies · $1,249 in 2025
The $1,249 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $175 · 2022: $97.50 · 2023: $289 · 2024: $799 · 2025: $1,249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,238 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,237.67 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $507.97 | 2021-2025 | Ultomiris |
| Genentech USA, INC. | $401.15 | 2021-2025 | Ocrevus |
| Takeda Pharmaceuticals U.S.A., INC. | $376.37 | 2024-2025 | Hyqvia, Cuvitru |
| Alnylam Pharmaceuticals INC. | $286.89 | 2024-2025 | Amvuttra |
| Amgen INC. | $265.45 | 2024-2025 | Evenity, Uplizna |
| Tg Therapeutics, INC. | $130.00 | 2025 | |
| Ucb, INC. | $108.95 | 2024-2025 | Zilbrysq, Rystiggo |
| Genzyme Corporation | $100.00 | 2023 | |
| Eisai INC. | $92.02 | 2024 | |
| Abbvie INC. | $60.98 | 2025 | |
| Glaxosmithkline, LLC. | $46.70 | 2023-2025 | Nucala |
| Tersera Therapeutics LLC | $43.08 | 2023-2025 | Quzyttir |
| Grifols USA, LLC | $38.17 | 2023-2025 | Gamunex-C |
| Janssen Biotech, INC. | $37.55 | 2024-2025 | Tremfya, Stelara |
| Argenx US, INC. | $36.31 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.38 | 2025 | |
| Chiesi USA, INC. | $21.11 | 2025 | Lamzede, Elfabrio |
| E.R. Squibb & Sons, L.L.C. | $17.28 | 2021 | |
| Grt US Holding, INC. | $11.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cherez Pouncey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.